Profoundbio Announces Completion Of More Than $55 Million Series A Financing To Advance Novel Antibody-Drug Conjugate (Adc) Portfolio

Jul 12, 2021•about 4 years ago

Amount Raised

$55 Million

Round Type

series a

Woodinville

Description

ProfoundBio announced the closing of a $55+ million Series A financing round led by Lilly Asia Venture and co-led by LYFE Capital, with participation from Sequoia Capital China and Oriza. All investors from the Series Pre-A financing, K2VC, Gaorong Capital, and Chang'an Capital, also participated in this round of financing.

Company Information

Company

Profound Bio

Location

Woodinville, Washington, United States

About

ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on innovative technology platforms, ProfoundBio has developed a pipeline consisting of multiple solid tumor-targeting drug candidates that are currently in discovery and preclinical development stages. ProfoundBio has operations in both the greater Seattle area, WA, USA and Suzhou, China. For more information, please visit www.profoundbio.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech